EDGAR·FLOW

Transcode Therapeutics, Inc. — Form 8-K

Filed September 28, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
TransCode reported updated Phase 1a data for TTX-MC138 (anti-miR-10b) as of September 1, 2026: 10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease; three patients remained progression-free at 12 months; disease control extended through six months in 35.7% of patients; no dose-limiting toxicities reported across all doses including 4.8 mg/kg; exploratory biomarker analysis showed treatment-associated antitumor immune activation. The study met its primary safety endpoint.
Why this rating

Early-stage oncology data with durable clinical signals in heavily pretreated population is materially positive for $6.5M-cap biotech; validates lead program justifying further development investment, though Phase 1a remains early-stage with small N and requires Phase 2 confirmation.

Tradability signal
SHORT conviction 21/100 · expected -0.59% over 4 hrs

SHORT (fade the pop): stock already ran +7.0% on this news, and positive calls in this cell have historically given the pop back (-0.70% over 4 hrs, n=130). Reversion play, lower conviction by design. Exit plan: HARD stop 5% against entry — default width (volatility unmeasured), fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$1.58 ▼ 6.51%
at our read · unknown
$1.69
+10 min · unknown
$1.76 ▲ 4.14%
+30 min · unknown
$1.70 ▲ 0.30%
+1 hr · unknown
$1.68 ▼ 0.59%
+4 hrs · unknown
$1.66 ▼ 1.78%

The stock had already moved +6.96% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ RNAZ · stock on Yahoo Finance ↗

See more from September 28, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.